BioPharmaTrend
Latest Insights
Companies
  • Companies Directory
  • Case Studies
Newsletter
About
  • At a Glance
  • Our Team
  • Advisory Board
  • Citations and Press Coverage
  • Partner Events Calendar
  • Advertise with Us
 
 Subscribe 
Sign in
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures
  • Business Intelligence

Andrii Buvailo, PhD

Science & Tech Communicator at www.AndriiBuvailo.com

Co-founder, BiopharmaTrend

   

Dr. Andrii Buvailo is a pharmaceutical industry analyst, tech scout and writer with a focus on artificial intelligence (AI) in drug discovery and biotech, digital transformation of pharma industry, and the advent of novel therapeutic modalities.

Andrii’s reports touch upon disruptive biotech startups, venture capital deals, drug discovery IPOs and platform companies. His articles were published on Forbes, and market research reports were referenced by some of the leading organizations (e.g. Deloitte).

Andrii is an ex-Enamine veteran, having served for the company as Director of E-commerce and Marketing for more than 8 years. Enamine is a global supplier of fine chemicals and compound libraries for the pharmaceutical industry.

Before venturing into the pharmaceutical industry and media entrepreneurship, Andrii used to work as a scientist. He holds PhD in Physical Chemistry, and has research experience in bioinorganic and supramolecular chemistry, thin polymer films, nanomaterials, and sensors.

Andrii is Ukrainian, currently based in Spain.


Recent articles from Andrii

When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides

Oct. 10, 2026      Interviews
When Agents Run Computations: Schrödinger’s Robert Abel On Where The Human Still Decides

Generating drug candidate ideas has become inexpensive, and the supply of hypotheses now exceeds any organization’s capacity to evaluate them. Schrödinger’s answer, launched at the end of July, is Bunsen: an agentic AI co-scientist that runs the company’s own …

WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies

Oct. 6, 2026      News
WhiteLab Genomics Raises $26M to Scale AI-designed Delivery Systems for Cell and Gene Therapies

Techbio company WhiteLab Genomics has raised a $26 million Series B to develop and license its own AI-designed gene delivery technologies, moving beyond the computational services business it started with.

Founded in 2019 by David Del Bourgo and Julien …

Is “Rescuing Failed Drugs with AI” a Category Now?

May 22, 2026      Business Intelligence
Is “Rescuing Failed Drugs with AI” a Category Now?

Inside the growing bet that AI can find the patients pharma's failed trials missed...

Update (October 2026): Five months after this piece was first published, Biossil raised another $153 million (C$216 million) at a $1 billion valuation, this …

The $2.7B Question: How Do We Know If Isomorphic's AI Works?

Sept. 30, 2026      Business Intelligence
The $2.7B Question: How Do We Know If Isomorphic's AI Works?

Isomorphic Labs has raised about $2.7 billion from outside investors since 2025. Its president, Max Jaderberg, says its drug design engine works, but the company has not publicly named a drug candidate.

Three AI Drug Discovery Startups Raise $526 Million in Two Days

Sept. 24, 2026      News
Three AI Drug Discovery Startups Raise $526 Million in Two Days

Three AI drug discovery companies raised a combined $526 million on September 23 and 24. One mines plants and microbes for new medicines. One trains its models on what it calls the world's largest proprietary genomic dataset. The third runs …

Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

Sept. 21, 2026      Business Intelligence
Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?

In the latest news, Novo Nordisk has entered a collaboration with Anthropic aimed at speeding the discovery and development of new medicines. An initial project will test Anthropic's Claude Science on specific R&D workflows where the companies expect the greatest …

The Bigger Point Beyond Insilico's Aging Research Milestone

Sept. 9, 2026      Business Intelligence
The Bigger Point Beyond Insilico's Aging Research Milestone

This week Insilico Medicine, an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a conventional disease indication. 

Six proteomic aging clocks were …

What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?

Sept. 5, 2026      Business Intelligence
What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?

Last week, Anthropic and OpenAI released new frontier models, specifically, Anthropic shipped Claude Fable 5.1 and a restricted variant called Mythos 5.1, while OpenAI shipped GPT-6 Astra.

OpenAI president, Greg Brockman went as far as suggesting this might …

Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

July 2, 2026      Business Intelligence
Could Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?

AlSO: The Numbers Behind China's Biopharma Ascent.

Everyone is talking about how Anthropic AI lab now designs drugs, hires the AlphaFold Nobel laureate, and ships Claude Science alongside Claude Code. Also, their partnership with Basecamp Research (i.e. EDEN-designed antibiotic …

Seven HealthTech Trends In Europe To Watch

June 26, 2026      Business Intelligence
Seven HealthTech Trends In Europe To Watch

I spent last week in Amsterdam, attending HLTH Europe 2026, arguably Europe's flagship healthcare innovation event, hosting more than 5,000 attendees. It is my second HLTH experience, and two additions to this year's program stood out: last year's Pharma & …

BiopharmaTrend.com

Where Tech Meets Bio
mail  Newsletter
in  LinkedIn
x  X
rss  RSS Feed

About


  • What we do
  • Press & Citations
  • Terms of Use
  • Privacy Policy
  • Cookies Policy
  • Disclaimer

Topics


  • News
  • AI in Bio
  • Tech Giants
  • Next-Gen Tools
  • Biotech Ventures

Explore


  • Premium Insights
  • Business Intelligence
  • Companies
  • Events
  • Authors

Partner


  • Sponsorship
  • Editorial Calendar

© WTMB Research & Media, S.L. (WTMB Group)   2026
We use cookies to personalise content and to analyse our traffic. You consent to our cookies if you continue to use our website. Read more details in our cookies policy.